methoxsalen (X-PACT) / Immunolight - LARVOL DELTA

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: Immunolight, LLC | N=20 ➔ 52

Enrollment change • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • ER • HER-2 • PD-L1 • PGR

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Immunolight, LLC | Trial completion date: Mar 2026 ➔ Mar 2029 | Trial primary completion date: Sep 2025 ➔ Sep 2028

Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer (clinicaltrials.gov) - P=N/A | N=0 | Available | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

New trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Immunolight, LLC | N=12 ➔ 20 | Trial completion date: Aug 2025 ➔ Mar 2026 | Trial primary completion date: Sep 2024 ➔ Sep 2025

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Immunolight, LLC | Trial completion date: Feb 2025 ➔ Aug 2025 | Trial primary completion date: Mar 2024 ➔ Sep 2024

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Immunolight, LLC | Trial primary completion date: Mar 2023 ➔ Mar 2024

Metastases • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor

Immunolight, LLC Now Recruiting Patients for Phase 1 Trial of the X-PACT System in Solid Tumors (PRNewswire) - "Immunolight LLC...announced today it is now recruiting patients for a phase 1 study of its X-PACT Cancer Treatment system in Breast, Melanoma, Sarcoma and Head and Neck Cancers, to be conducted at Duke University Medical Center."

Trial status • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Immunolight, LLC; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Immunolight, LLC; Trial completion date: Feb 2023 ➔ Feb 2025; Trial primary completion date: Jul 2021 ➔ Mar 2023

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Immunolight, LLC Receives FDA Clearance to Initiate Phase 1 Trial of the X-PACT System in Solid Tumors (PRNewswire) - "Immunolight, LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it has received FDA clearance to enter phase 1 study in patients with breast, melanoma, sarcoma and head and neck cancers. The heart of the X-PACT (X-ray Psoralen Activated Cancer Treatment) system is psoralen, a naturally occurring compound which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers."

IND • Breast Cancer • Head and Neck Cancer • Melanoma • Oncology • Sarcoma